Shuf turns any medical content into a new format with AI so that you can increase your audience

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

Shuf turns any medical content into a new format with AI so that you can increase your audience

The RUBY trial demonstrates that disrupting the BCL11A binding site in the γ-globin promoters can normalize hemoglobin in severe sickle cell disease.

The next frontier is not only building constructs that reduce one mechanism of relapse, but understanding why antigen-positive failures still occur.

Jeremy Bellaiche: Episode 5 of The Translational Edge With Yan Leyfman on Exercise in Cancer Care / cancer, Jeremy Bellaiche, OncoDaily, Oncology, The

A landmark Nature study demonstrates targeted CRISPR-based CAR transgene integration in living patients' T cells without ex vivo manufacturing.

Yan Leyfman, MD, reflected on resilience and hope in the face of cancer, recounting a 37-year-old diagnosed with stage IV colorectal cancer followed by HIV.

Yan Leyfman: Clinicians Must Shape How AI Impacts Patient Care / AI, cancer, OncoDaily, Oncology, Yan Leyfman

This section aims to enhance provider empathy, mitigate burnout, and center the patient’s lived experience within the rigorous framework of medical science.

Yan Leyfman: Seeing Trainees Move from Learners to Published Authors / Ariana Pelosci, cancer, Chandler Park, Ishan Paduvagere, Jenna Ghazal, MedNews Week,

Yan Leyfman: Why ASCT Remains Foundational Amid Modern Myeloma Advances / ASCT, cancer, Chandler H Park, Ishan Paduvagere, Jenna Ghazal, multiple myeloma,

Yan Leyfman: Survey for Real-World Insights on AI Use in Medicine / cancer, OncoDaily, Oncology, Yan Leyfman

Thank you for participating in this survey on the use of artificial intelligence (AI) in oncology practice. This anonymous survey explores how oncology clinicians interact with different AI tools in ...

MedHELM, an extensible evaluation framework including a new taxonomy for classifying medical tasks and a benchmark of many datasets across these categories, enables the evaluation of large language mo...

The anterior cingulate cortex encodes affective pain behaviours modulated by opioids; targeting opioid-sensitive neurons through a new chemogenetic gene therapy replicates the analgesic effects of mor...

Identifying what aspects of brain activity are responsible for conscious perception remains one of the most challenging problems in science. While pro…

Shuf turns any medical content into a new format with AI so that you can increase your audience

Yan Leyfman: Adipose Manipulation Transplantation as a New Cancer Therapy Platform / cancer, OncoDaily, Oncology, Pancreatic Cancer, Yan Leyfman

Yan Leyfman: Uncovering Site-Specific Immune and Stromal Differences in Primary and Metastatic PDAC / Alyssa M. Krasinskas, Ayana T. Ruffin, Bassel F.

Yan Leyfman: New Evidence Highlights the Power of the Patient Voice in Oncology / Ali Benour, Andrea Bezjak, Andrew Mihalache, cancer, Carlton Johnny, David

Yan Leyfman: MedNews Week Celebrates 4-Year Anniversary / Alexandra Van de Kieft, Arturo Loaiza-Bonilla, cancer, Chandler H Park, Gayathri Pramil Menon, Ghena

Yan Leyfman: A Global, Volunteer Model for Accurate and Inclusive Cancer Education / cancer, MedNews Week, OncoDaily, Oncology, Yan Leyfman

Yan Leyfman: Ultra-Processed Foods and Early-Onset Colorectal Neoplasia / Alberto Puccini, cancer, colorectal cancer, Colorectal Neoplasia, David Foureau,

Yan Leyfman: Brian Van Tine - The Truly Great Ones Leave Us Far Too Soon / Brian Van Tine, cancer, OncoDaily, Oncology, Yan Leyfman

Experts explore the messy intersection between evidence-based cancer care and an enticing wellness industry dominated by social media influencers who often spread cancer misinformation.

The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.

Yan Leyfman: Honored to Join the Advisory Board of CancerNetwork / cancer, CancerNetwork, OncoDaily, Oncology, ONCOLOGY/CancerNetwork, Yan Leyfman

Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL / Bristol Myers Squibb, cancer, FDA,

Key Points. Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity.Talquetamab enabled transition

Pathogenic variants in mitochondrial DNA (mtDNA) are a common cause of severe, often fatal, inherited metabolic disease. A reproductive care pathway was implemented to provide women carrying pathog...

Yan Leyfman: AI's Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma / C. Huang, C. Xie, cancer, Cancer research, F. Xie, F. Zhong, J. Chen,

A large single-cell transcriptomic-based reference model for hematopoietic stem and progenitor cells from 148 age- and sex-diverse individuals identifies physiological and disease-specific changes acr...